Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
clinical trials
4
×
life sciences
national blog main
rna interference
4
×
alnylam pharmaceuticals
boston top stories
deals
national top stories
alexion pharmaceuticals
alirocumab
amgen
boehringer ingelheim
boston
evolocumab
fda
hepatitis b
inclisiran
new york
new york blog main
new york top stories
pcsk9 inhibitors
regeneron pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
dicerna pharamceuticals
dicerna pharmaceuticals
drugs
eli lilly
evercore isi
heart attack
hepatitis b virus
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
johnson & johnson
joseph swartz
medicines co.
neurodegenerative diseases
What
medicines
4
×
drug
cholesterol
deal
dicerna
long
medco
new
pharma
pharmaceuticals
rna
abandoning
acquire
ago
agreed
alnylam
baggage
based
billion
brings
cash
caught
causing
companies
company
compound
cuts
data
development
disease
evidence
eye
fda
free
gene
gets
heart
hepatitis
intended
interference
Language
unset
Current search:
biotech
×
medicines
×
" clinical trials "
×
" rna interference "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M